Does Phenylephrine Really Control Allergic Rhinitis Symptoms?


Allergic rhinitis is a condition that keeps noses and pharmacists running.

Allergic rhinitis is a condition that keeps noses and pharmacists running.

During peak allergy seasons, patients bombard pharmacists with questions about OTC relief because their symptoms diminish quality of life, interfere with sleep, limit activities, cause work and school absences, create moodiness, and decrease concentration.

Treatment with decongestants and antihistamines typically curbs symptoms.

Given the more restricted access to pseudoephedrine because of its potential for abuse, OTC phenylephrine hydrochloride is a common and frequent substitute. It may be more convenient at first, but does it really control allergic rhinitis symptoms?

In 2007, the FDA recommended further study of phenylephrine hydrochloride to assess its efficacy and safety for allergic rhinitis. This action came after a citizen petition was filed.

In January 2016, The Annals of Allergy, Asthma, and Immunology published a study that showed phenylephrine hydrochloride tablets were no more effective than placebo.

Phenylephrine hydrochloride has been plagued with poor bioavailability. When the 10 mg immediate-release tablets were studied, their peak effect was shown to dramatically diminish after 1.5 hours. The idea to formulate a modified-release tablet addressed patient adherence and bioavailability issues.

One randomized, double-blinded, placebo control trial evaluated phenylephrine hydrochloride 30 mg modified-release tablets in patients with nasal congestion. This formulation was expected to provide constant phenylephrine hydrochloride levels for 12 hours. For 7 days, the researchers followed 575 participants taking either placebo or phenylephrine twice daily, 12 hours apart.

The investigators assessed difference from baseline over the entire course of treatment based on patients' use of a standardized tool called the reflective daily nasal score. Patients recorded their scores in a diary, and the score averaged patients’ morning and nighttime assessments of nasal congestion.

No significant difference in congestion was noted between the 288 phenylephrine hydrochloride-treated patients and 287 placebo patients. Safety profiles were also similar.

The modified-release formulation didn’t seem to be equivalent or more effective than the immediate-release formulations.

The study recommended that guidelines should be altered to steer patients toward more effective treatments for allergic rhinitis and concluded that phenylephrine hydrochloride is no better than placebo.

Allergic rhinitis, also known as hay fever, affects more than 50 million Americans.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.